Antimicrobial

Leadership Team

Permanent surface treatments to 

These surfaces are slippery (nearly superhydrophobic)  and reduce resistance between material surfaces or the environment, essentially allowing for self-cleaning surfaces.

Principal and Founder

Randy Clevenger, Ph.D.

"Antimicrobial" generally refers to the killing of bacteria, fungi, and molds. MST creates surfaces that very quickly and potently kill bacteria and fungi, keeping materials microbe free.

differentiate your product line

Biologically-active surface modifications can advance cellular adhesion and growth directly on the material surface, allowing for improved, more economic, and environmentally-friendly biologic activity.

Target Applications

Our proprietary technology creates functional surfaces by modifying the outermost layer of a material with various molecules that impart that function. Our treatments are not coatings or paints - they are formed through stable covalent bonds, giving them excellent stability in a wide variety of conditions.

Bioactive

  • Orthopaedic spine surgeon, entrepreneur, and cofounder/board member of multiple successful startup ventures
  • Founding Partner at K2M (purchased by Stryker) and Electrocore (recently went public, NASDAQ: ECOR).

Covalent Advantage

Provides novel, proprietary improvement of products

Stable attachment of molecules to surfaces

Science-Driven

​MST is a science and technology company dedicated to developing and licensing/selling its surface treatment technologies to companies who manufacturer/distribute end products. From a development point of view, we invent, refine, and provide a final surface modification strategy for specific products to meet our development partner company’s needs. This may include all scientific and technical support to achieve regulatory approval and scalable manufacturing.

Technology Characteristics

Lubricious

Principal and Chief Scientific Officer

Gordon D. Donald, M.D.

​​​Our focus is on three broad categories of functionalized surfaces:

Thin treatments that do not impact bulk properties of the substrate

  • Former Vice President of Research and Development at Orthobond
  • Extensive experience in the covalent attachment of active end groups to various substrates and achieving goals for regulatory approval